Implication of Circulating Extracellular Vesicles-Bound Amyloid-β42 Oligomers in the Progression of Alzheimer's Disease

被引:2
|
作者
Ben Khedher, Mohamed Raafet [1 ,2 ,3 ]
Haddad, Mohamed [1 ,2 ]
Fulop, Tamas [4 ]
Laurin, Danielle [2 ,5 ,6 ]
Ramassamy, Charles [1 ,2 ]
机构
[1] INRS, Ctr Armand Frappier Sante Biotechnol, Laval, PQ, Canada
[2] Inst Nutr & Funct Foods, Quebec City, PQ, Canada
[3] Univ Jendouba, Higher Inst Biotechnol Beja, Beja, Tunisia
[4] Univ Sherbrooke, Res Ctr Aging, Div Geriatr, Dept Med, Sherbrooke, PQ, Canada
[5] Univ Laval, CHU Quebec, VI TAM Ctr Rech Sante Durable, Ctr Excellence Vieillissement Quebec,Res Ctr, Quebec City, PQ, Canada
[6] Laval Univ, Fac Pharm, Quebec City, PQ, Canada
关键词
Alzheimer's disease; amyloid-beta; apolipoprotein J; extracellular vesicles; BLOOD-BRAIN-BARRIER; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA; EXOSOMES; RECEPTOR; HAPTOGLOBIN; MICROGLIA; PATHWAY; TAU;
D O I
10.3233/JAD-230823
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: The perplex interrelation between circulating extracellular vesicles (cEVs) and amyloid-beta (A beta) deposits in the context of Alzheimer's disease (AD) is poorly understood. Objective: This study aims to 1) analyze the possible cross-linkage of the neurotoxic amyloid-beta oligomers (oA beta) to the human cEVs, 2) identify cEVs corona proteins associated with oA beta binding, and 3) analyze the distribution and expression of targeted cEVs proteins in preclinical participants converted to AD 5 years later (Pre-AD). Methods: cEVs were isolated from 15 Pre-AD participants and 15 healthy controls selected from the Canadian Study of Health and Aging. Biochemical, clinical, lipid, and inflammatory profiles were measured. oA beta and cEVs interaction was determined by nanoparticle tracking analysis and proteinase K digestion. cEVs bound proteins were determined by ELISA. Results: oA beta were trapped by cEVs and were topologically bound to their external surface. We identified surface-exposed proteins functionally able to conjugate oA beta including apolipoprotein J (apoJ), apoE and RAGE, with apoJ being 30- to 130-fold higher than RAGE and apoE, respectively. The expression of cEVs apoJ was significantly lower in Pre-AD up to 5 years before AD onset. Conclusions: Our findings suggest that cEVs might participate in oA beta clearance and that early dysregulation of cEVs could increase the risk of conversion to AD.
引用
收藏
页码:813 / 825
页数:13
相关论文
共 50 条
  • [31] Extracellular vesicles in Alzheimer's disease: from pathology to therapeutic approaches
    Garcia-Contreras, Marta
    Thakor, Avnesh S.
    NEURAL REGENERATION RESEARCH, 2023, 18 (01) : 18 - 22
  • [32] Increased Total Tau But Not Amyloid-β42 in Cerebrospinal Fluid Correlates with Short-Term Memory Impairment in Alzheimer's Disease
    Lin, Yuh-Te
    Cheng, Jiin-Tsuey
    Yao, Yun-Chin
    Juo, Liang-I
    Lo, Yuk-Keung
    Lin, Ching-Hwung
    Ger, Luo-Ping
    Lu, Pei-Jung
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (04) : 907 - 918
  • [33] Inhibition of Amyloid-β Aggregation in Alzheimer's Disease
    Wang, Qiuming
    Yu, Xiang
    Li, Lingyan
    Zheng, Jie
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (08) : 1223 - 1243
  • [34] Amyloid-β: A double agent in Alzheimer's disease?
    Yu, Hao
    Wu, Jie
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [35] Amyloid-β-directed immunotherapy for Alzheimer's disease
    Lannfelt, L.
    Relkin, N. R.
    Siemers, E. R.
    JOURNAL OF INTERNAL MEDICINE, 2014, 275 (03) : 284 - 295
  • [36] Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimer's Disease
    Silva, D. F. F.
    Esteves, A. R.
    Oliveira, C. R.
    Cardoso, S. M.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (05) : 563 - 572
  • [37] The amyloid-β pathway in Alzheimer's disease: a plain language summary
    Hampel, Harald
    Hu, Yan
    Hardy, John
    Blennow, Kaj
    Chen, Christopher
    Perry, George
    Kim, Seung Hyun
    Villemagne, Victor L.
    Aisen, Paul
    Vendruscolo, Michele
    Iwatsubo, Takeshi
    Masters, Colin L.
    Cho, Min
    Lannfelt, Lars
    Cummings, Jeffrey L.
    Vergallo, Andrea
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2023, 13 (03) : 141 - 149
  • [38] Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer's Disease
    Kim, Dong Eun
    Priefer, Ronny
    BRAIN SCIENCES, 2020, 10 (02)
  • [39] Update on amyloid- homeostasis markers for sporadic Alzheimer's disease
    Zetterberg, Henrik
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2009, 69 (01) : 18 - 21
  • [40] Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer's disease
    Saiz-Sanchez, Daniel
    De la Rosa-Prieto, Carlos
    Ubeda-Banon, Isabel
    Martinez-Marcos, Alino
    BRAIN STRUCTURE & FUNCTION, 2015, 220 (04) : 2011 - 2025